← Leaderboards
Brad Kahl
University Of Wisconsin Madison
$3,632,482
Attributed
$4,051,469
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $621K · FY2008–14$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,051,469 · 3
By mechanism
U10$4,030,670 · 2
M01$20,799 · 1
Top collaborators
- David M Kushner1 shared
- Mark A Ritter1 shared
- Lee Gravatt Wilke1 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- James A Stewart$6,121,809
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchProgramsCancer BurdenLeadershipDesignClinical TrialsInstitutionCancer CareWisconsinMalignant NeoplasmsCommitFacultyGrantAffectUniversitiesParticipantCancer TherapyEastern Cooperative Oncology GroupPreventionEvaluationCategoriesData QualityComprehensive Cancer CenterAnticancer Research
Grant awards (8)
National Clinical Trials Network Research at the University of Wisconsin$558,650
U10 · FY2014 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$496,942
U10 · FY2013 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$564,359
U10 · FY2012 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$564,359
U10 · FY2011 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$614,774
U10 · FY2010 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$620,983
U10 · FY2009 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$610,603
U10 · FY2008 · CA · contact PI
Phase I Study of Rituximab with L2-7001 (Aldesleukin) for Non-Hodgkin's Lymphoma$20,799
M01 · FY2004 · RR